Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus XIFYRM.
MYCHEL vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
Adults: 200 mg orally twice daily for 14 days.
500 mg orally twice daily with food.
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category C
Category C
Antibiotic
Antibiotic